| 1.66 -0.05 (-2.92%) | 06-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.35  |
1-year : | 2.6 |
| Resists | First : | 2.01 |
Second : | 2.23 |
| Pivot price | 1.82 |
|||
| Supports | First : | 1.65 |
Second : | 1.38 |
| MAs | MA(5) : | 1.73 |
MA(20) : | 1.86 |
| MA(100) : | 1.82 |
MA(250) : | 1.99 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 3.8 |
D(3) : | 7.7 |
| RSI | RSI(14): 38 |
|||
| 52-week | High : | 2.79 | Low : | 1.32 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IMMP ] has closed below the lower bollinger band by 0.1%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 15.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.72 - 1.73 | 1.73 - 1.74 |
| Low: | 1.63 - 1.64 | 1.64 - 1.66 |
| Close: | 1.64 - 1.66 | 1.66 - 1.68 |
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
Tue, 27 May 2025
Breakthrough: Immutep's Triple Therapy Shows 3X Better Results in Rare Cancer Treatment Trial - Stock Titan
Thu, 15 May 2025
Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo - Benzinga
Thu, 15 May 2025
Immutep reports promising lung cancer trial results - Investing.com
Thu, 15 May 2025
Is Immutep Limited (IMMP) the Best Australian Stock to Buy According to Analysts? - Insider Monkey
Thu, 08 May 2025
Immutep Limited: Surging On Positive Head And Neck Data (NASDAQ:IMMP) - Seeking Alpha
Mon, 05 May 2025
Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 146 (M) |
| Shares Float | 1,230 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 1.9 (%) |
| Shares Short | 4,100 (K) |
| Shares Short P.Month | 4,130 (K) |
| EPS | -0.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.11 |
| Profit Margin | 0 % |
| Operating Margin | -839.3 % |
| Return on Assets (ttm) | -20.4 % |
| Return on Equity (ttm) | -30.5 % |
| Qtrly Rev. Growth | 49 % |
| Gross Profit (p.s.) | -0.29 |
| Sales Per Share | 0.03 |
| EBITDA (p.s.) | -0.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -45 (M) |
| Levered Free Cash Flow | -32 (M) |
| PE Ratio | -7.22 |
| PEG Ratio | 0 |
| Price to Book value | 13.83 |
| Price to Sales | 49.51 |
| Price to Cash Flow | -5.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|